Abstract
This article reports on the short-term findings of a randomized, double-blind, placebo-controlled crossover trial that demonstrated the prowess of the glucagon-like peptide-1 analogue liraglutide, used as an adjunct to insulin, in promoting glycemic control in type 1 diabetes [Heller SR et al. EASD 2013 (abstr 3); NCT01536665].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
